These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 22593043)
1. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response. Zhong Y; Zhang F; Sun Z; Zhou W; Li ZY; You QD; Guo QL; Hu R Mol Carcinog; 2013 Oct; 52(10):824-34. PubMed ID: 22593043 [TBL] [Abstract][Full Text] [Related]
2. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. Xu X; Zhang Y; Li W; Miao H; Zhang H; Zhou Y; Li Z; You Q; Zhao L; Guo Q Biochem Pharmacol; 2014 Nov; 92(2):220-34. PubMed ID: 25264278 [TBL] [Abstract][Full Text] [Related]
3. Wogonin-enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by suppression Nrf2-mediated signaling in HepG2 cells. Qian C; Wang Y; Zhong Y; Tang J; Zhang J; Li Z; Wang Q; Hu R Free Radic Res; 2014 May; 48(5):607-21. PubMed ID: 24666416 [TBL] [Abstract][Full Text] [Related]
4. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697 [TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment. Venkatraman G; Benesch MG; Tang X; Dewald J; McMullen TP; Brindley DN FASEB J; 2015 Mar; 29(3):772-85. PubMed ID: 25398768 [TBL] [Abstract][Full Text] [Related]
6. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway. Huang KF; Zhang GD; Huang YQ; Diao Y Int Immunopharmacol; 2012 Feb; 12(2):334-41. PubMed ID: 22182776 [TBL] [Abstract][Full Text] [Related]
7. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation. Zhang ZL; Jiang QC; Wang SR Breast Cancer; 2018 Mar; 25(2):233-242. PubMed ID: 29181822 [TBL] [Abstract][Full Text] [Related]
8. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway. Chian S; Li YY; Wang XJ; Tang XW Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924 [TBL] [Abstract][Full Text] [Related]
9. Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. Liu WH; Chang LS Int J Biochem Cell Biol; 2011 Dec; 43(12):1708-19. PubMed ID: 21854868 [TBL] [Abstract][Full Text] [Related]
10. Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation. Xu X; Zhang X; Zhang Y; Yang L; Liu Y; Huang S; Lu L; Kong L; Li Z; Guo Q; Zhao L Sci Rep; 2017 Feb; 7():39950. PubMed ID: 28150717 [TBL] [Abstract][Full Text] [Related]
11. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines. Gao HL; Xia YZ; Zhang YL; Yang L; Kong LY Phytomedicine; 2019 May; 58():152885. PubMed ID: 31009836 [TBL] [Abstract][Full Text] [Related]
12. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008 [TBL] [Abstract][Full Text] [Related]
13. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559 [TBL] [Abstract][Full Text] [Related]
14. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Gao AM; Ke ZP; Shi F; Sun GC; Chen H Chem Biol Interact; 2013 Oct; 206(1):100-8. PubMed ID: 23994249 [TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Chen CC; Chu CB; Liu KJ; Huang CY; Chang JY; Pan WY; Chen HH; Cheng YH; Lee KD; Chen MF; Kuo CC; Chen LT Biochem Pharmacol; 2013 Oct; 86(7):872-87. PubMed ID: 23933386 [TBL] [Abstract][Full Text] [Related]
16. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin. Scherbakov AM; Lobanova YS; Andreeva OE; Shatskaya VA; Krasil'nikov MA Biosci Rep; 2011 Apr; 31(2):137-43. PubMed ID: 20662767 [TBL] [Abstract][Full Text] [Related]
17. Allicin Overcomes Doxorubicin Resistance of Breast Cancer Cells by Targeting the Nrf2 Pathway. Shi G; Li X; Wang W; Hou L; Yin L; Wang L Cell Biochem Biophys; 2024 Jun; 82(2):659-667. PubMed ID: 38411783 [TBL] [Abstract][Full Text] [Related]
18. Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression. Chen B; Zhang Y; Wang Y; Rao J; Jiang X; Xu Z J Steroid Biochem Mol Biol; 2014 Sep; 143():11-8. PubMed ID: 24486718 [TBL] [Abstract][Full Text] [Related]
19. Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway. Chen JM; Bai JY; Yang KX IUBMB Life; 2018 Jun; 70(6):491-500. PubMed ID: 29637742 [TBL] [Abstract][Full Text] [Related]
20. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways. Park SJ; Wu CH; Safa AR Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]